330 related articles for article (PubMed ID: 2655259)
1. [Short-term versus long-term chemoprevention of recurrence with Epodyl following transurethral resection of superficial urinary bladder cancer].
Flamm J; Kühnel W; Dona S
Urologe A; 1989 Mar; 28(2):99-102. PubMed ID: 2655259
[TBL] [Abstract][Full Text] [Related]
2. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
3. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
[TBL] [Abstract][Full Text] [Related]
4. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
5. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
[TBL] [Abstract][Full Text] [Related]
6. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
[TBL] [Abstract][Full Text] [Related]
7. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.
Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M
Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial.
Goebell PJ; Otto T; Suhr J; Rübben H
J Urol; 2002 Jul; 168(1):72-5. PubMed ID: 12050495
[TBL] [Abstract][Full Text] [Related]
11. Intravesical chemotherapy for superficial bladder tumors category Ta/T1: who should be treated and how?
Kurth KH
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):30-5. PubMed ID: 8727808
[TBL] [Abstract][Full Text] [Related]
12. Treatment schedule of intravesical chemotherapy with mitomycin C in superficial bladder cancer: short-term courses or maintenance therapy.
van der Meijden AP; DeBruyne FM
Urology; 1988 Mar; 31(3 Suppl):26-9. PubMed ID: 3126592
[TBL] [Abstract][Full Text] [Related]
13. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function.
Hinotsu S; Akaza H; Ohashi Y; Kotake T
Cancer; 1999 Nov; 86(9):1818-26. PubMed ID: 10547556
[TBL] [Abstract][Full Text] [Related]
14. [Instillation chemotherapy with peplomycin in superficial bladder cancer: clinical study on the effects of the direct antitumor activity and of the prophylaxis of recurrence].
Sonoda T; Osafune M; Matsuda M; Usami M
Hinyokika Kiyo; 1988 Mar; 34(3):574-81. PubMed ID: 2455442
[TBL] [Abstract][Full Text] [Related]
15. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
[TBL] [Abstract][Full Text] [Related]
16. Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer.
Maffezzini M; Simonato A; Zanon M; Raber M; Carmignani G
J Urol; 1996 Jan; 155(1):91-3. PubMed ID: 7490907
[TBL] [Abstract][Full Text] [Related]
17. [Short-term intravesical instillation of pirarubicin (THP) in prophylactic treatment after transurethral resection of superficial bladder tumor].
Kuroda K; Ishii N; Fukasawa K; Shirai M; Tajima M; Matsushima M; Miura K; Takanami M; Matsuhashi M; Kuwabara T; Matsumoto H; Sugita M
Hinyokika Kiyo; 1998 Aug; 44(8):547-52. PubMed ID: 9783189
[TBL] [Abstract][Full Text] [Related]
18. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
Huncharek M; McGarry R; Kupelnick B
Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
[TBL] [Abstract][Full Text] [Related]
19. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
[TBL] [Abstract][Full Text] [Related]
20. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Herr HW
J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
